Trial reportBritish journal of cancer2017
HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
Trial report in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Risk-Based Triage Using Cytology and HPV Genotyping to Reduce Unnecessary Colposcopy: A Real-World Cross-Sectional Study.Biomedicines · 2026Article
- HPV persistence and CIN2 + Detection in women with normal cytology and Non-16/18 High-Risk HPV positivity.BMC women's health · 2026Article
- Immune Dysregulation and Viral Persistence in HPV-HIV Coinfection: Oncogenic and Clinical Implications.HIV/AIDS (Auckland, N.Z.) · 2026Review
- Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 study.Infectious agents and cancer · 2025Article
- Cervical HPV infection and related diseases among 149,559 women in Fujian: an epidemiological study from 2018 to 2023.Frontiers in microbiology · 2024Article
- The human Papillomavirus twilight zone - Latency, immune control and subclinical infection.Tumour virus research · 2023Review
- Validation of an on-chip p16Scientific reports · 2023Article
- Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.BMJ (Clinical research ed.) · 2022Observational
- Which is the best management for women with normal cervical cytologic findings despite positivity for non-16/18 high risk human papillomaviruses?Frontiers in public health · 2022Review
- HPV and the Risk of HIV Acquisition in Women.Frontiers in cellular and infection microbiology · 2022Review
- Screening for cervical cancer: Choices & dilemmas.The Indian journal of medical research · 2021Review
- Introducing human papillomavirus (HPV) primary testing in the age of HPV vaccination: projected impact on colposcopy services in Wales.BJOG : an international journal of obstetrics and gynaecology · 2021Article
- Recall Efforts Successfully Increase Follow-Up for Cervical Cancer Screening Among Women With Human Papillomavirus in Honduras.Global health, science and practice · 2020Article
- Article
- Diagnostic excision of the cervix in women over 40 years with human papilloma virus persistency and normal cytology.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
- Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans.Papillomavirus research (Amsterdam, Netherlands) · 2019Article
- Article
- Primary cervical screening with high risk human papillomavirus testing: observational study.BMJ (Clinical research ed.) · 2019Observational
- Cervical cancer screening history prior to a diagnosis of cervical cancer in Danish women aged 60 years and older-A national cohort study.Cancer medicine · 2019Article
- Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.Viruses · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two screening rounds needs to be assessed.
methodsWe compared the 5-year risk of HPV infection and CIN3+ in HPV-pos/cyt-neg women with a negative repeat HPV test to the risk in HPV-negative women with normal cytology (double negatives) in the POBASCAM cohort. We obtained histology data from the Dutch pathology registry (PALGA).
resultsHuman papillomavirus infection risk was 20.4% (19 of 93) in HPV-pos/cyt-neg, repeat HPV-negative women and 3.2% (294 of 9186; P<0.001) in double negatives. Corresponding CIN3+ risks were 2.0% (4 of 199) and 0.2% (41 of 18 562; P<0.001). Infection risks were also increased in type-specific analyses of HPV16, 31, 33, 39, 52, 56 and 58.
conclusionsHPV-pos/cyt-neg women continue to have an increased CIN3+ risk, also when the repeat HPV test is negative. Therefore, intervals in primary HPV screening should be determined separately for HPV-positive and -negative women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.